Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Director · CEO | July 27, 2026 | July 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date July 27, 2026 · Filed July 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 98,845 |
Reported balance
After 2026-07-27 transaction · row 1
1 source rowRow 1 · 2026-07-27 · Gift · Disposed 319.6499 · Balance 98,845 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 11,836.201 |
Reported balance
After 2026-07-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-07-27 · Gift · Acquired 319.6499 · Balance 11,836.201 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 8,915.6499 |
Reported balance
After 2026-07-27 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-07-27 · Sale · Disposed 2,920.5511 · Balance 8,915.6499 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 3,733.5603 |
Reported balance
Holding disclosure · report date 2026-07-27 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 3,733.5603 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2017 Filed May 15, 2017 21:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009777 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · CVP, Surgical Heart Valves 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,102.4816 F1 · shares: These restricted stock units were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 20,000 | $0.00 Strike: $66.86 | $0.00 |
DisclosureSEC source: 0001225208-17-008603 · doc4.xml · derivative · entry 3 Zovighian Bernard J · CIK 0001665141 · CVP, Surgical Heart Valves 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,556 Underlying: Common Stock · 20,000 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 18,050 | $109.21 | $1,971,318.12 |
DisclosureSEC source: 0001225208-17-008603 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · CVP, Surgical Heart Valves 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,552.4816 F2 · price: This transaction was executed in multiple trades at prices ranging from $109.21 to $109.7550. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 20,000 | $66.86 | $1,337,200.00 |
DisclosureSEC source: 0001225208-17-008603 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · CVP, Surgical Heart Valves 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,602.4816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| September 14, 2016 Filed Sep 15, 2016 23:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 436 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-039416 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · CVP, Surgical Heart Valves 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,450.0977 F1 · shares: These restricted stock units were granted on September 14, 2016 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.